|
Synonyms: Tumor necrosis factor ligand superfamily member 15, membrane form
Compound class:
Endogenous peptide in human, mouse or rat
Comment: TL1A occurs as both membrane‐bound and soluble forms. It principally functions as a negative modulator of epithelial cell proliferation. Inhibiting the TL1A/death receptor 3 (TNFRSF25) pathway has been proposed as mechanism to treat inflammatory bowel disease [1]. In addition, TL1A has been associated with tumourigenesis and progression of some gastrointestinal malignancies [3,5,7], making it a target of interest for the development of novel anti-cancer drugs.
Species: Human
|
| No information available. |
Summary of Clinical Use  |
| TL1A is being evaluated as a therapeutic target as a novel mechanism for ulcerative colitis treatment. PF-06480605 is a first-in-class TL1A blocking monoclonal antibody that inhibits pro-inflammatory cytokine production by T cell subsets [1]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04090411 | A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis | Phase 2 Interventional | Pfizer | 1 | |
